Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (11-20 of 168) with videos related to

Pageof 17
Sort By:
Expert Review of Anti-Infective Therapy|April 14, 2025
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrowMilo Gatti, Federico Pea
Infection and Drug Resistance|March 23, 2026
Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor CombinationsMilo Gatti, Federico Pea
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 14, 2026
Re: 'Pharmacokinetics, target attainment and outcomes of piperacillin/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis' by Chiriac et alMilo Gatti, Federico Pea
Infectious Disease Reports|January 21, 2026
Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?Milo Gatti, Federico Pea
Clinical Pharmacokinetics|January 30, 2021
Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?Milo Gatti, Federico Pea
Expert Review of Clinical Pharmacology|March 9, 2021
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitorsMilo Gatti, Federico Pea
The Journal of Antimicrobial Chemotherapy|April 13, 2023
Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infectionsMilo Gatti, Federico Pea
Antimicrobial Agents and Chemotherapy|November 6, 2024
Are the pharmacokinetic data of meropenem studied in CSF of a mixed population composed of patients with cerebral infections and patients with extracerebral infections really helpful for clinicians treating CNS infections?Milo Gatti, Federico Pea
Expert Review of Clinical Pharmacology|October 24, 2023
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swanMilo Gatti, Federico Pea
Pharmaceutics|March 6, 2021
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesMilo Gatti, Fabrizio De Ponti
Pageof 17

Showing results (11-20 of 168) with videos related to

Sort By:
Pageof 17
Expert Review of Anti-Infective Therapy|April 14, 2025
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrowMilo Gatti, Federico Pea
Infection and Drug Resistance|March 23, 2026
Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor CombinationsMilo Gatti, Federico Pea
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 14, 2026
Re: 'Pharmacokinetics, target attainment and outcomes of piperacillin/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis' by Chiriac et alMilo Gatti, Federico Pea
Infectious Disease Reports|January 21, 2026
Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?Milo Gatti, Federico Pea
Clinical Pharmacokinetics|January 30, 2021
Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?Milo Gatti, Federico Pea
Expert Review of Clinical Pharmacology|March 9, 2021
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitorsMilo Gatti, Federico Pea
The Journal of Antimicrobial Chemotherapy|April 13, 2023
Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infectionsMilo Gatti, Federico Pea
Antimicrobial Agents and Chemotherapy|November 6, 2024
Are the pharmacokinetic data of meropenem studied in CSF of a mixed population composed of patients with cerebral infections and patients with extracerebral infections really helpful for clinicians treating CNS infections?Milo Gatti, Federico Pea
Expert Review of Clinical Pharmacology|October 24, 2023
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swanMilo Gatti, Federico Pea
Pharmaceutics|March 6, 2021
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesMilo Gatti, Fabrizio De Ponti
Pageof 17